Your browser doesn't support javascript.
loading
Association between Crohn's disease and AarF domain-containing kinase 4 glomerulopathy.
Kakiuchi, Toshihiko; Ohtsuka, Yasufumi; Sato, Tadashi; Nakayama, Aiko; Jinnouchi, Kumiko; Oka, Masafumi; Matsuo, Muneaki.
Afiliación
  • Kakiuchi T; Department of Pediatrics, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga-shi, Saga, 849-8501, Japan. kakiucht@cc.saga-u.ac.jp.
  • Ohtsuka Y; Department of Pediatrics, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga-shi, Saga, 849-8501, Japan.
  • Sato T; Department of Pediatrics, Ureshino Medical Center, 2436, Shimojuku-hei, Oaza, Ureshino-machi, Ureshino-shi, Saga, 843-0393, Japan.
  • Nakayama A; Department of Pediatrics, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga-shi, Saga, 849-8501, Japan.
  • Jinnouchi K; Department of Pediatrics, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga-shi, Saga, 849-8501, Japan.
  • Oka M; Department of Pediatrics, Ureshino Medical Center, 2436, Shimojuku-hei, Oaza, Ureshino-machi, Ureshino-shi, Saga, 843-0393, Japan.
  • Matsuo M; Department of Pediatrics, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga-shi, Saga, 849-8501, Japan.
Clin J Gastroenterol ; 12(3): 263-268, 2019 Jun.
Article en En | MEDLINE | ID: mdl-30706428
Coenzyme Q10 deficiency causing gastrointestinal symptoms has not been reported. At least 15 genes are involved in CoQ10 biosynthesis, and one of the genes is AarF domain-containing kinase 4 (ADCK4). This case report first showed a patient who presented with Crohn's disease (CD) combined with ADCK4 glomerulopathy (ADCK4-GN). After approximately 2 years of infliximab treatment for CD, this patient has remained in clinical remission with no adverse effects. Moreover, two important findings were obtained: first, individuals with ADCK4-GN may present with complications, such as CD, which is a gastrointestinal disease, and infliximab may be effective for CD associated with ADCK4-GN. Second, infliximab may also be effective and safe for individuals with CD who are undergoing peritoneal dialysis. Thus, the results of the present study may be used in managing patients with such condition, and as a result, better clinical outcomes will be obtained.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Quinasas / Fármacos Gastrointestinales / Enfermedad de Crohn / Infliximab / Glomerulonefritis Tipo de estudio: Risk_factors_studies Límite: Adolescent / Humans / Male Idioma: En Revista: Clin J Gastroenterol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Proteínas Quinasas / Fármacos Gastrointestinales / Enfermedad de Crohn / Infliximab / Glomerulonefritis Tipo de estudio: Risk_factors_studies Límite: Adolescent / Humans / Male Idioma: En Revista: Clin J Gastroenterol Año: 2019 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón